Predict clinical success before the first patient is dosed. Leleka BIO™ turns living patient tumors and multi-omics data into an AI “digital twin” capable to assess drug efficacy, resistance for optimal trial stratification—delivering better early decisions, shorter timelines, lower costs, and higher confidence for oncology R&D.
The Challenge
90 % of oncology assets that look “promising” in cell-line and mouse studies still fail in the clinic. Immortalized lines and PDXs simply can’t capture human tumor heterogeneity or real-world biology.
Our Solution
Leleka BIO™ unites an ethically sourced biobank of 3D patient-derived tumor models with a multi-layer AI engine that learns directly from paired clinical outcomes.
How Leleka BIO™ Works
